Anda di halaman 1dari 3

In families with the inherited form of retinoblastoma, the disease shows an autosomal dominant inheritance

Clinical Presentation The most common presenting sign is leukocoria (white pupillary reflex). A crossed
eye or strabismus is the second most common symptom of retinoblastoma. The child's eye may turn towards
the ear (exotropia) or towards the nose (esotropia). Other symptoms may include red painful eye, glaucoma,
pseudohypopyon (appearance of purulent material in the anterior chamber of the eye), or poor vision
Enukleasi adalah suatu tindakan pengambilan seluruh bolamata dengan mempertahankan jaringan orbita
yang lain.
Eksenterasi adalah suatu tindakan pengambilan seluruh atau sebagian jaringan orbita beserta bolamata
Beberapa tahun yang lalu, enukleasi masih merupakan satu-satunya terapi retinoblastoma. Meskipun
tindakan ini dapat menyelamatkan hidup pada banyak kasus, akan tetapi mengakibatkan keterbatasan
penglihatan dan erat kaitannya dengan beberapa masalah yang biasa terjadi akibat anophthalmic socket,
yaitu masalah kosmetik, sindroma mata kering dan infeksi. Selanjutnya, ditemukan alternatif terapi dengan
external beam radiation therapy yang dapat mempertahankan bola mata bahkan beberapa kasus masih
terdapat penglihatan. Akan tetapi external beam radiation therapy ternyata juga menimbulkan beberapa
masalah yaitu sindroma mata kering, katarak, retinopati, deformitas kosmetik dan keganasan sekunder.
Radioactive plaque brachytherapy, fotokoagulasi laser dan terapi krio merupakan terapi alternatif mengatasi
masalah akibat external beam radiation therapy, hanya saja tindakan ini berguna pada keadaan tumor yang
kecil dan recurrent tumor akibat external beam radiation therapy. Akhir-akhir ini yang populer dan banyak
digunakan adalah teknik chemoreduction dan chemothermotherapy dengan tujuan mengurangi ukuran tumor
sehingga metode konservatif lain dapat digunakan

Focal therapy
Laser therapy

Most centres use transpupillary 532-nm or 810-nm lasers through the indirect ophthalmoscope in the
management of Rb tumours. The 1064-nm laser is useful for thick and recurrent tumours after
chemotherapy. Both the infrared lasers (810 nm and 1064 nm) can also be delivered trans-sclerally.
Cryotherapy is used to treat tumours anterior to the equator of the retina or to increase access of
chemotherapeutic drugs into the vitreous (pre-chemotherapy cryotherapy)46 (see Treatment chapter).
Cryotherapy digunakan untuk mengobati tumor anterior ke khatulistiwa retina atau untuk
meningkatkan akses obat kemoterapi ke dalam vitreous (cryotherapy pra-kemoterapi) 46
(lihat "Treatment" bab).

Many pilot studies of chemotherapy to treat Rb have been reported, but have yet to be validated by
randomized controlled trials.47 Treatment of bilateral Rb currently involves chemotherapy with carboplatin,
etoposide, and vincristine, with or without additional cyclosporine A. Medical staff (including oncologists,
nurses, and pharmacists) experienced in the use of these drugs for treatment of Rb supervise this therapy (see
Treatment chapter).
Radiotherapy is not commonly used now for primary treatment of Rb. When other means of saving the last
remaining eye have failed, external beam radiation (EBR) may be given, preferably with modern precision to
minimize dose to bone. Radioactive plaque therapy (brachytherapy) is occasionally useful for specific
primary or recurrent focal tumours.
Ocular imaging
The wide-angle digital retinal camera, RetCamTM, has become standard in Rb treatment centres worldwide
to capture high-resolution images of the posterior and peripheral retina in children for sequential comparison
of tumour progression or regression over time. Scleral depression, in combination with RetCamTM imaging,
allows documentation of tumours up to the ora serrata. When used by an experienced imaging specialist, the
RetCamTM can better detect Rb tumours at an early stage, when treatment required is minimal, than the
indirect ophthalmoscope.
Fluorescein angiograms with the RetCamTM reveal areas of tumour vascularization. Regular B-scan 2D
ophthalmic ultrasound is an important tool to document intraocular calcification as strong evidence
supporting a diagnosis of
Rb. High frequency ultrasound such as ultrasound biomicroscopy (UBM) is particularly useful to assess
anterior disease behind the iris, where it cannot otherwise be observed. Often the clinicians operate the
imaging tools, but some centres employ imaging specialists who contribute valuable expertise to the team.
The digital capture capability of the RetCamTM and ultrasound devices allows ophthalmologists to
overcome distance, and easily consult with each other in difficult or challenging cases through telemedicine.
The characteristic calcification within the Rb tumour is well detected by the widely available B-scan 2D
ocular ultrasound.
While computed tomography (CT) has previously been widely used in assessing eyes with large tumours for
extraocular disease, it is now recognized that the radiation dose delivered by CT scan may increase risk of
secondary non-Rb malignant neoplasms in children with RB1+/- germline mutation (see Genetic Analysis
chapter).48,49 Magnetic resonance imaging (MRI) of the head and orbits is therefore now preferred to image
Rb upon presentation due to increased image resolution and avoidance of radiation, although it is generally
less easy to access. MRI of the head and orbit confirms the Rb intraocular tumour, evaluates the extent of the
Rb and screens for trilateral intracranial tumour.50,51
Genetic counselling
Rb-specific genetic counselling requires detailed knowledge of the biology of Rb and the interpretation of
RB1 mutation test results and implications. Blood and (or) tumour are sent to a reference laboratory with
published high sensitivity for RB1 testing (see Genetic Analysis chapter). Multidisciplinary centres
interpret the results and direct the management of the child based on the results. Family members who carry

the germline mutation, or whose risk of developing Rb is not clarified by genetic testing, are examined for
Rb or retinoma

Table 7. International Intraocular Rb Classification (IIRC)45

Group A: Very low risk
Small discrete tumours not threatening vision (T1a)
All tumours are 3 mm or smaller, confined to the retina
Located at least 3 mm from the foveola and 1.5 mm from the optic nerve
No vitreous or subretinal seeding
Group B: Low risk
No vitreous or subretinal seeding (T1b)
Tumours any size or location not in Group A
No vitreous or subretinal seeding
Subretinal fluid no more than 5 mm from tumour base
Group C: Moderate risk (T2)
Focal vitreous or subretinal seeding and discrete retinal tumours of any
size and location
Local, fine, and limited seeding (T3)
Discrete intraretinal tumours of any size and location (T2b)
Up to one quadrant of subretinal fluid (T2a)
Group D: High risk
Diffuse vitreous or subretinal seeding (T3b)
Diffuse intraocular disseminated disease
Extensive or greasy vitreous seeding
Subretinal seeding may be plaque-like
More than one quadrant retinal detachment
Group E: Very high risk (T4a)
Very high risk with one or more of the following:
Irreversible neovascular glaucoma
Massive intraocular hemorrhage
Aseptic orbital cellulitis
Tumour anterior to anterior vitreous face
Tumour touching the lens
Diffuse infiltrating Rb
Phthisis or prephthisis